Li Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Li Wang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Erhao Bao
Department of Urology, Sichuan Provincial People’s Hospital East Sichuan & Dazhou First People’s Hospital, Dazhou City Traditional Chinese Medicine Industry Incubation Center, Dazhou City Traditional Chinese Medicine Research Center
1 shared publication - Hui Shuai
Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan
1 shared publication - Huiyu Gao
Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan
1 shared publication - Jia Hao Wang
Department of Urology, Nanchong Psychosomatic Hospital, Nanchong, Sichuan, China
1 shared publication - Jiabin Zhang
Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan
1 shared publication Jing-Ya Deng
Chongqing Youth Vocational & Technical College, Chongqing, China
1 shared publication
Latest Publications
- 2 March 2025
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 19 (1) , 1-2
Comment on: “Transperitoneal vs retroperitoneal robotic partial nephrectomy: a meta-analysis and systematic review of propensity-matched studies”
- 2 March 2025
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 19 (1) , 1-2
Comment on: “Transperitoneal vs retroperitoneal robotic partial nephrectomy: a meta-analysis and systematic review of propensity-matched studies”
- Open Access
- 25 July 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (1) , 311-321
Metabolic syndrome and cancer risk: a two-sample Mendelian randomization study of European ancestry
Background: The relationship between Metabolic Syndrome and cancer remains controversial. The authors aimed to assess the association between Metabolic Syndrome and cancer risk at different locations using a Mendelian randomization approach. Methods: The authors extracted single nucleotide polymorphisms (SNPs) of MetS and its components from public databases for populations of European ancestry. Causal effects were estimated using inverse variance weighting, MR-Egger, weighted median, and MR-PRESSO. Sensitivity analyses were performed using Cochran’s Q test, MR-Egger intercept test, MR-PRESSO, leave-one-out analysis, and funnel plots. In addition, the authors calculated the Statistical power. Finally, the authors applied the False Discovery Rate (FDR) to correct our results. Results: IVW methods showed that Genetically predicted Metabolic Syndrome may be a potential risk factor for hepatocellular carcinoma ( P =0.031, P-FDR=0.093). Metabolic Syndrome was not causally associated with cancers at other sites (lung, thyroid, breast, prostate, kidney, bladder, colorectal, esophagus, and stomach). In further analyses, WC may increase the risk of lung ( P =0.003, P-FDR=0.018), and esophageal ( P =0.011, P-FDR=0.066) cancers and decrease the risk of prostate cancer ( P =0.006, P-FDR=0.001). Furthermore, hypertension may reduce the risk of Hepatic cancer ( P =0.014, P-FDR=0.084). Conclusion: Our study suggests that genetically predicted Metabolic Syndrome may increase the risk of some cancers. Prevention and treatment of Metabolic Syndrome may help to prevent the development of related cancers.
- 25 July 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (1) , 311-321
Open AccessMetabolic syndrome and cancer risk: a two-sample Mendelian randomization study of European ancestry
Background: The relationship between Metabolic Syndrome and cancer remains controversial. The authors aimed to assess the association between Metabolic Syndrome and cancer risk at different locations using a Mendelian randomization approach. Methods: The authors extracted single nucleotide polymorphisms (SNPs) of MetS and its components from public databases for populations of European ancestry. Causal effects were estimated using inverse variance weighting, MR-Egger, weighted median, and MR-PRESSO. Sensitivity analyses were performed using Cochran’s Q test, MR-Egger intercept test, MR-PRESSO, leave-one-out analysis, and funnel plots. In addition, the authors calculated the Statistical power. Finally, the authors applied the False Discovery Rate (FDR) to correct our results. Results: IVW methods showed that Genetically predicted Metabolic Syndrome may be a potential risk factor for hepatocellular carcinoma ( P =0.031, P-FDR=0.093). Metabolic Syndrome was not causally associated with cancers at other sites (lung, thyroid, breast, prostate, kidney, bladder, colorectal, esophagus, and stomach). In further analyses, WC may increase the risk of lung ( P =0.003, P-FDR=0.018), and esophageal ( P =0.011, P-FDR=0.066) cancers and decrease the risk of prostate cancer ( P =0.006, P-FDR=0.001). Furthermore, hypertension may reduce the risk of Hepatic cancer ( P =0.014, P-FDR=0.084). Conclusion: Our study suggests that genetically predicted Metabolic Syndrome may increase the risk of some cancers. Prevention and treatment of Metabolic Syndrome may help to prevent the development of related cancers.
- Open Access
- 3 March 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-10
Causal relationship between gut microbiota and prostate cancer contributes to the gut-prostate axis: insights from a Mendelian randomization study
Background: Changes in gut microbiota abundance have been linked to prostate cancer development. However, the causality of the gut-prostate axis remains unclear. Methods: The genome-wide association study (GWAS) data for gut microbiota sourced from MiBioGen (n = 14,306), alongside prostate cancer summary data from PRACTICAL (n = 140,254) and FinnGen Consortium (n = 133,164). Inverse-variance-weighted (IVW) was mainly used to compute odds ratios (OR) and 95% confidence intervals (Cl), after diligently scrutinizing potential sources of heterogeneity and horizontal pleiotropy via the rigorous utilization of Cochran's Q test, the MR-PRESSO method, and MR-Egger. We used meta-analysis methods in random effects to combine the Mendelian randomization (MR) estimates from the two sources. Results: The pooled analyses of MR results show that genus Eubacterium fissicatena (OR = 1.07, 95% CI 1.01 to 1.13, P = 0.011) and genus Odoribacter (OR = 1.14, 95% CI 1.01 to 1.27, P = 0.025) were positively associated with prostate cancer. However, genus Adlercreutzia (OR = 0.89, 95% CI 0.83 to 0.96, P = 0.002), Roseburia (OR = 0.90, 95% CI 0.83 to 0.99, P = 0.03), Holdemania (OR = 0.92, 95% CI 0.86 to 0.97, P = 0.005), Flavonifractor (OR = 0.85, 95% CI 0.74 to 0.98, P = 0.024) and Allisonella (OR = 0.93, 95% CI 0.89 to 0.98, P = 0.011) seems to be a protective factor for prostate cancer. Sensitivity analysis found no significant heterogeneity, horizontal pleiotropy, or reverse causal links in all causal associations. Conclusion: This MR study lends support to a causal relationship between genetically predicted gut microbiota and prostate cancer. Research on the gut-prostate axis, along with further multi-omics analyses, holds significant implications for the prevention and treatment of prostate cancer.
- 3 March 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-10
Open AccessCausal relationship between gut microbiota and prostate cancer contributes to the gut-prostate axis: insights from a Mendelian randomization study
Background: Changes in gut microbiota abundance have been linked to prostate cancer development. However, the causality of the gut-prostate axis remains unclear. Methods: The genome-wide association study (GWAS) data for gut microbiota sourced from MiBioGen (n = 14,306), alongside prostate cancer summary data from PRACTICAL (n = 140,254) and FinnGen Consortium (n = 133,164). Inverse-variance-weighted (IVW) was mainly used to compute odds ratios (OR) and 95% confidence intervals (Cl), after diligently scrutinizing potential sources of heterogeneity and horizontal pleiotropy via the rigorous utilization of Cochran's Q test, the MR-PRESSO method, and MR-Egger. We used meta-analysis methods in random effects to combine the Mendelian randomization (MR) estimates from the two sources. Results: The pooled analyses of MR results show that genus Eubacterium fissicatena (OR = 1.07, 95% CI 1.01 to 1.13, P = 0.011) and genus Odoribacter (OR = 1.14, 95% CI 1.01 to 1.27, P = 0.025) were positively associated with prostate cancer. However, genus Adlercreutzia (OR = 0.89, 95% CI 0.83 to 0.96, P = 0.002), Roseburia (OR = 0.90, 95% CI 0.83 to 0.99, P = 0.03), Holdemania (OR = 0.92, 95% CI 0.86 to 0.97, P = 0.005), Flavonifractor (OR = 0.85, 95% CI 0.74 to 0.98, P = 0.024) and Allisonella (OR = 0.93, 95% CI 0.89 to 0.98, P = 0.011) seems to be a protective factor for prostate cancer. Sensitivity analysis found no significant heterogeneity, horizontal pleiotropy, or reverse causal links in all causal associations. Conclusion: This MR study lends support to a causal relationship between genetically predicted gut microbiota and prostate cancer. Research on the gut-prostate axis, along with further multi-omics analyses, holds significant implications for the prevention and treatment of prostate cancer.